Literature DB >> 23709681

Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells.

Tao Wu1, James S Young, Heather Johnston, Xiong Ni, Ruishu Deng, Jeremy Racine, Miao Wang, Audrey Wang, Ivan Todorov, Jianmin Wang, Defu Zeng.   

Abstract

Prevention of chronic graft-versus-host disease (cGVHD) remains a major challenge in allogeneic hematopoietic cell transplantation (HCT) owing to limited understanding of cGVHD pathogenesis and lack of appropriate animal models. In this study, we report that, in classical acute GVHD models with C57BL/6 donors and MHC-mismatched BALB/c recipients and with C3H.SW donors and MHC-matched C57BL/6 recipients, GVHD recipients surviving for >60 d after HCT developed cGVHD characterized by cutaneous fibrosis, tissue damage in the salivary gland, and the presence of serum autoantibodies. Donor CD8(+) T cells were more potent than CD4(+) T cells for inducing cGVHD. The recipient thymus and de novo-generated, donor-derived CD4(+) T cells were required for induction of cGVHD by donor CD8(+) T cells but not by donor CD4(+) T cells. Donor CD8(+) T cells preferentially damaged recipient medullary thymic epithelial cells and impaired negative selection, resulting in production of autoreactive CD4(+) T cells that perpetuated damage to the thymus and augmented the development of cGVHD. Short-term anti-CD4 mAb treatment early after HCT enabled recovery from thymic damage and prevented cGVHD. These results demonstrate that donor CD8(+) T cells cause cGVHD solely through thymic-dependent mechanisms, whereas CD4(+) T cells can cause cGVHD through either thymic-dependent or independent mechanisms.

Entities:  

Mesh:

Year:  2013        PMID: 23709681      PMCID: PMC3746979          DOI: 10.4049/jimmunol.1300657

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Graft-versus-host-disease-associated thymic damage results in the appearance of T cell clones with anti-host reactivity.

Authors:  M R van den Brink; E Moore; J L Ferrara; S J Burakoff
Journal:  Transplantation       Date:  2000-02-15       Impact factor: 4.939

2.  Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation.

Authors:  Defu Zeng; Petra Hoffmann; Fengshuo Lan; Philip Huie; John Higgins; Samuel Strober
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

3.  Emergence of T cells that recognize nonpolymorphic antigens during graft-versus- host disease.

Authors:  Hemalatha Rangarajan; Maryam Yassai; Hariharan Subramanian; Richard Komorowski; Megan Whitaker; Jack Gorski; William R Drobyski
Journal:  Blood       Date:  2012-04-10       Impact factor: 22.113

4.  Equal opportunity targeting in chronic GVHD.

Authors:  Allan D Hess
Journal:  Blood       Date:  2012-06-28       Impact factor: 22.113

5.  Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease.

Authors:  James S Young; Tao Wu; Yuhong Chen; Dongchang Zhao; Hongjun Liu; Tangsheng Yi; Heather Johnston; Jeremy Racine; Xiaofan Li; Audrey Wang; Ivan Todorov; Defu Zeng
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

6.  Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.

Authors:  M Ito; J A Shizuru
Journal:  Biol Blood Marrow Transplant       Date:  1999       Impact factor: 5.742

7.  Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation.

Authors:  Yan Zhang; Laura L McCormick; Snehal R Desai; Caiyun Wu; Anita C Gilliam
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

Review 8.  Are we making progress in GVHD prophylaxis and treatment?

Authors:  Steven Z Pavletic; Daniel H Fowler
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

Review 9.  Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment.

Authors:  Anthony D Sung; Nelson J Chao
Journal:  Stem Cells Transl Med       Date:  2012-12-19       Impact factor: 6.940

10.  Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease.

Authors:  Simona Rossi; Bruce R Blazar; Catherine L Farrell; Dimitry M Danilenko; David L Lacey; Kenneth I Weinberg; Werner Krenger; Georg A Holländer
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

View more
  71 in total

1.  Proinflammatory Dual Receptor T Cells in Chronic Graft-versus-Host Disease.

Authors:  Amritha Balakrishnan; Nicholas Gloude; Roman Sasik; Edward D Ball; Gerald P Morris
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-24       Impact factor: 5.742

Review 2.  B-cell targeting in chronic graft-versus-host disease.

Authors:  Robert Zeiser; Stefanie Sarantopoulos; Bruce R Blazar
Journal:  Blood       Date:  2018-02-01       Impact factor: 22.113

3.  Vitamin C stabilizes CD8+ iTregs and enhances their therapeutic potential in controlling murine GVHD and leukemia relapse.

Authors:  Supinya Iamsawat; Linlu Tian; Anusara Daenthanasanmak; Yongxia Wu; Hung D Nguyen; David Bastian; Xue-Zhong Yu
Journal:  Blood Adv       Date:  2019-12-23

4.  PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.

Authors:  Kathryn W Juchem; Faruk Sacirbegovic; Cuiling Zhang; Arlene H Sharpe; Kerry Russell; Jennifer M McNiff; Anthony J Demetris; Mark J Shlomchik; Warren D Shlomchik
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

5.  B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease.

Authors:  Ruishu Deng; Kaniel Cassady; Xiaofan Li; Sheng Yao; Mingfeng Zhang; Jeremy Racine; Jeffrey Lin; Lieping Chen; Defu Zeng
Journal:  J Immunol       Date:  2014-12-08       Impact factor: 5.422

6.  Tissue-resident PSGL1loCD4+ T cells promote B cell differentiation and chronic graft-versus-host disease-associated autoimmunity.

Authors:  Xiaohui Kong; Deye Zeng; Xiwei Wu; Bixin Wang; Shijie Yang; Qingxiao Song; Yongping Zhu; Martha Salas; Hanjun Qin; Ubaydah Nasri; Karen M Haas; Arthur D Riggs; Ryotaro Nakamura; Paul J Martin; Aimin Huang; Defu Zeng
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

7.  SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Authors:  Jonathan C Poe; Wei Jia; Julie A Di Paolo; Nancy J Reyes; Ji Yun Kim; Hsuan Su; John S Sundy; Adela R Cardones; Victor L Perez; Benny J Chen; Nelson J Chao; Diana M Cardona; Daniel R Saban; Stefanie Sarantopoulos
Journal:  JCI Insight       Date:  2018-10-04

8.  Newly found arsons ignite the fire of gut GVHD.

Authors:  Defu Zeng
Journal:  J Clin Invest       Date:  2018-01-29       Impact factor: 14.808

Review 9.  Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.

Authors:  Kelli P A MacDonald; Geoffrey R Hill; Bruce R Blazar
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

10.  Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation.

Authors:  Erin Gatza; Sung Won Choi
Journal:  Int J Hematol Oncol       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.